



ASX ANNOUNCEMENT

Lumos Receives Research & Development Tax Rebate

MELBOURNE, Australia (5 August 2024) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to announce that it has received a cash refund of A\$140,777 related to its Research and Development Tax Incentive for the FY2023 financial year ended 30 June 2023.

This cash refund primarily relates to the continued R&D conducted by Lumos on the development and optimization of its benchtop and disposable proprietary reader technology platform. This device enables testing of a greater range of clinical biomarkers, facilitating the reading and interpretation of results from point-of-care diagnostic tests and enabling them to seamlessly interface with electronic medical record systems. This reader platform has been a highly valued element of the Lumos service offering to clients and has been instrumental in recent contract wins with Hologic and the Burnet Diagnostics Initiative of the MacFarlane Burnet Institute for Medical Research and Public Health Ltd.

The Australian Government’s Research and Development Tax Incentive Refund provides eligible companies with cash refunds for 43.5% of eligible expenditure on research and development activities.

Doug Ward, CEO and Managing Director of Lumos Diagnostics commented, “The R&D Tax Incentive program plays an important role in offsetting some of the costs associated with the activities required to bring new Lumos Diagnostics technologies to market. This federal government program allows us to extend and accelerate the amount of R&D which we can undertake in Australia and is an important source of non-dilutive funding.”

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia

HACK Director

haley@hck.digital

+61 423 139 163

Investor Contact:

Jane Lowe

Managing Director, IR Department

ir@lumosdiagnostics.com

+61 411 117 774

Company Registered Office:

Lumos Diagnostics Holdings Ltd

Level 4, 100 Albert Rd

South Melbourne, VIC 3205

info@lumosdiagnostics.com

+61 3 9087 1598